Trials / Completed
CompletedNCT01245387
Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration
Long-Term Non-Interventional Study (AB Study) To Investigate The Efficacy And Safety Of Macugen® In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,001 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Long-term observational study to assess the safety, efficacy and quality of life of patients with neovascular age-related macular degeneration (AMD) under Macugen treatment.
Detailed description
Ophthalmologists who are experienced in doing intravitreal injections in Germany
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegaptanib | Dosage recommendations for MACUGEN took place on the basis of the approved Summary of Product Characteristics (SmPC) and were adjusted solely according to medical practice. MACUGEN® is available as pre-filled syringe containing 0.3 mg MACUGEN® in 90 µL injection solution for intravitreal injection. Macugen injections were documented to reflect the routine clinical practice. Follow-up visits were only carried out and documented if they took place as part of the standard medical treatment for the respective case and were necessary for medical and/or therapeutic reasons. |
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2010-11-22
- Last updated
- 2011-01-13
- Results posted
- 2011-01-07
Source: ClinicalTrials.gov record NCT01245387. Inclusion in this directory is not an endorsement.